{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:21:02Z","timestamp":1792480862887,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104805","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:27:05Z","timestamp":1781627225000},"page":"104805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-2562","authenticated-orcid":false,"given":"Pauline","family":"Corbaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-8857","authenticated-orcid":false,"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle L.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-2019","authenticated-orcid":false,"given":"Fabien","family":"Subtil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"P\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-6381","authenticated-orcid":false,"given":"Karen","family":"Carty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-3470","authenticated-orcid":false,"given":"Olivier","family":"Colomban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Karamouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-1680","authenticated-orcid":false,"given":"Rosalind M.","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Yanaihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ijgc.2026.104805_bib1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104805_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.ijgc.2026.104805_bib3","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104805_bib4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104805_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102294","article-title":"The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas","volume":"100","author":"You","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers14010098","article-title":"The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian cancer: a narrative review","volume":"14","author":"Lauby","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijgc.2026.104805_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112966","article-title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: a Gynaecologic Cancer Intergroup meta-analysis","volume":"191","author":"Corbaux","year":"2023","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104805_bib8","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-18-3335","article-title":"Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU study","volume":"25","author":"Colomban","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104805_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa026","article-title":"Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7)","volume":"4","author":"Colomban","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104805_bib10","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-022-01732-7","article-title":"Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era","volume":"127","author":"You","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104805_bib12","article-title":"Benefit from fractionated dose-dense chemotherapy in patients with poor prognostic ovarian cancer: ICON-8 trial","volume":"7","author":"Colomban","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"34","key":"10.1016\/j.ijgc.2026.104805_bib13","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.22.00430","article-title":"CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA\/GOG-3005 study","volume":"41","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104805_bib15","unstructured":"Circulating tumor biomarker - biomarker Kinetics. Biomarker Kinetics. Accessed December 26, 2021. https:\/\/www.biomarker-kinetics.org\/presentation."},{"issue":"6","key":"10.1016\/j.ijgc.2026.104805_bib16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial","volume":"30","author":"Wu","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104805_bib17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104805_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104805_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(22)00283-2","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial","volume":"23","author":"Clamp","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18939","article-title":"Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis","volume":"3","author":"Paoletti","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104805_bib21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104805_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104805_bib23","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/annonc\/mds060","article-title":"First-line treatment of advanced ovarian cancer with paclitaxel\/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG","volume":"23","author":"Lindemann","year":"2012","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104805_bib24","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104805_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104805_bib26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.bjc.6604026","article-title":"Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group","volume":"97","author":"Ray-Coquard","year":"2007","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104805_bib27","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized Phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","article-title":"The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from Calypso trial (a GINECO-GCIG study)","volume":"130","author":"You","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104805_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.ijgc.2026.104805_bib31","series-title":"NONMEM User\u2019s Guides (1989-2009)","author":"Beal","year":"2009"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104805_bib32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/psp4.12422","article-title":"NONMEM tutorial Part II: Estimation methods and advanced examples","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104805_bib33","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1158\/1078-0432.CCR-16-1119","article-title":"Racial\/ethnic disparities in ovarian cancer treatment and survival","volume":"22","author":"Bandera","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41416-023-02471-z","article-title":"Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population","volume":"130","author":"Arter","year":"2024","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2019.05.013","article-title":"Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: an NRG Oncology\/GOG Ancillary study of 7914 patients","volume":"154","author":"Fuh","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104805_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2024.10.017","article-title":"Disparities in ovarian cancer survival among ethnic Asian American populations, 2006\u20132020","volume":"191","author":"Lee","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","article-title":"Bevacizumab combined with platinum\u2013taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)","volume":"24","author":"Komiyama","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104805_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102688","article-title":"SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer","volume":"35","author":"Chiva","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104805_bib39","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.ijgc.2026.104805_bib40","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104805_bib41","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104805_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101645","article-title":"Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and\/or fallopian tube cancer: the international HALO study","volume":"35","author":"Khokhlova","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/cas.15518","article-title":"Japanese nationwide observational multicenter study of tumor BRCA1\/2 variant testing in advanced ovarian cancer","volume":"114","author":"Oda","year":"2023","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70143","article-title":"The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer","volume":"15","author":"Su","year":"2025","journal-title":"Clin Transl Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib45","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2021.32.e49","article-title":"The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer","volume":"32","author":"Tokunaga","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104805_bib46","doi-asserted-by":"crossref","first-page":"S718","DOI":"10.1016\/j.annonc.2025.08.1704","article-title":"ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III\u2013IV epithelial ovarian cancer (EOC): final overall survival (OS) analysis","volume":"36","author":"Clamp","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102893","article-title":"ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III\u2013IV epithelial ovarian cancer: final overall survival (OS) analysis","volume":"36","author":"Clamp","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102892","article-title":"Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +\/\u2212 bevacizumab : pooled analysis of ICON8 and ICON8B phase III trials","volume":"36","author":"You","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2019.02.023","article-title":"Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women","volume":"153","author":"Lawrenson","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104805_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104805_bib51","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/genes12071050","article-title":"Differences in ovarian and other cancers risks by population and BRCA mutation location","volume":"12","author":"Sekine","year":"2021","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104805_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425250902800153","article-title":"Ethnic differences in drug metabolism and toxicity from chemotherapy","volume":"5","author":"Phan","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104805_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trecan.2020.10.014","article-title":"Uncovering mitochondrial determinants of racial disparities in ovarian cancer","volume":"7","author":"Shukla","year":"2021","journal-title":"Trends Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:45:25Z","timestamp":1788813925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26003361"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104805","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104805"}}